Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis by Carter, Hannah et al.
Effectiveness and cost-effectiveness of sentinel lymph node biopsy
compared with axillary node dissection in patients with early-stage
breast cancer: a decision model analysis
H Verry*,1, SJ Lord1, A Martin1, G Gill2, CK Lee1, K Howard3, N Wetzig4 and J Simes1
1NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, New South Wales 2050, Australia; 2Department of Surgery,
University of Adelaide, Adelaide, South Australia 5005, Australia; 3School of Public Health, University of Sydney, Edward Ford Building A27, Camperdown,
New South Wales 2006, Australia; 4Wesley Medical Centre, Sandford Jackson Building, 30 Chasely Street, Brisbane, Queensland 4066, Australia
BACKGROUND: Sentinel lymph node biopsy (SLNB) is less invasive than axillary lymph node dissection (ALND) for staging early breast
cancer, and has a lower risk of arm lymphoedema and similar rates of locoregional recurrence up to 8 years. This study estimates the
longer-term effectiveness and cost-effectiveness of SLNB.
METHODS: A Markov decision model was developed to estimate the incremental quality-adjusted life years (QALYs) and costs of an
SLNB-based staging and management strategy compared with ALND over 20 years’ follow-up. The probability and quality-of-life
weighting (utility) of outcomes were estimated from published data and population statistics. Costs were estimated from the
perspective of the Australian health care system. The model was used to identify key factors affecting treatment decisions.
RESULTS: The SLNB was more effective and less costly than the ALND over 20 years, with 8 QALYs gained and $883 000 saved per
1000 patients. The SLNB was less effective when: SLNB false negative (FN) rate413%; 5-year incidence of axillary recurrence after
an SLNB FN419%; risk of an SLNB-positive result 448%; lymphoedema prevalence after ALND o14%; or lymphoedema utility
decrement o0.012.
CONCLUSION: The long-term advantage of SLNB over ALND was modest and sensitive to variations in key assumptions, indicating a
need for reliable information on lymphoedema incidence and disutility following SLNB. In addition to awaiting longer-term trial data,
risk models to better identify patients at high risk of axillary metastasis will be valuable to inform decision-making.
British Journal of Cancer (2012) 106, 1045 – 1052. doi:10.1038/bjc.2012.62 www.bjcancer.com
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Sentinel lymph node biopsy (SLNB) has been widely adopted as a
less invasive surgical alternative to axillary lymph node dissection
(ALND) for staging early breast cancer. When SLNB indicates
axillary disease is not present, patients may be spared ALND
surgery. This strategy reduces the risk of immediate complications
and long-term arm morbidity, such as lymphoedema, for patients
at low risk of nodal metastasis.
Over the last decade, clinical trials comparing the effectiveness
of SLNB and ALND have randomised over 9000 patients with early
breast cancer (Mansel et al, 2006; Veronesi et al, 2006; Zavagno
et al, 2008; Canavese et al, 2009; Gill, 2009; Krag et al, 2010).
They have demonstrated that SLNB reduces the risk of arm morbi-
dity and lymphoedema, and shortens the postoperative hospital
stay without significantly increasing locoregional recurrence or
survival, with two trials reporting data at mean follow-up times
of approximately 8 years (Krag et al, 2010; Veronesi et al 2010).
Clinical guidelines recommend SLNB, by a team experienced in
SLNB mapping and excision, as the standard of care for axillary
staging for patients with clinically node-negative disease.
Despite the advantages of SLNB, unanswered questions remain.
Sentinel lymph node biopsy carries a risk of false negative (FN)
findings, with published estimates varying from 0–29% (meta-
analysis summary estimate 7.0%, Kim et al, 2006). Longer follow-
up data are needed to quantify the impact of FN findings on
locoregional recurrence and survival, and the longer-term benefits
of avoiding ALND, to help counsel patients. In particular, evidence
on patient or tumour factors that define groups who may not be
appropriate candidates for SLNB is lacking. For example, the
benefit of SLNB for patients with large tumours remains unclear.
Four of six published SLNB trials restricted eligibility to patients
with tumours less than 2–3 cm (Veronesi et al, 2006; Zavagno et al,
2008; Canavese et al, 2009; Gill, 2009). Only two ongoing trials,
NSABP 32 and ALMANAC, included patients with operable
tumours of any size, with 20–25% of subjects having a tumour
larger than 2 cm (Mansel et al, 2006; Krag et al, 2010).
Decision analysis synthesises the best available evidence in a
systematic way to provide estimates of longer-term outcomes
for different interventions over a range of clinical scenarios.
This approach can be used to explicitly demonstrate how current
trial evidence applies to different patient subgroups, and allows
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this evidence to be combined with subjective patient-rated
preferences (utilities; Drummond et al, 2005) and the financial
implications of treatment strategies.
The aim of this study was to develop a decision analytic model
to estimate the 20-year effectiveness and cost-effectiveness of SLNB
compared with ALND in the management of patients with early
breast cancer. We explore the implications of extending SLNB to
patients with a relatively high risk of lymph node metastasis,
to provide estimates of efficacy where limited trial data exist.
A secondary aim was to identify assumptions in the model, where
little evidence was available, that were critical to conclusions, to
highlight research priorities where more evidence is needed to
inform decision-making.
METHODS
A decision model was developed to estimate the benefits, risks and
costs of a staging and management strategy, based on SLNB
compared with ALND over a 20-year time horizon in a simulated
cohort of patients with early breast cancer and baseline
characteristics similar to patients in the Australian Sentinel Node
Axillary Clearance (SNAC) trial (Gill, 2009).
To define risk estimates for inclusion in the model, we reviewed
six published, randomised controlled trials comparing SLNB and
ALND that have reported on one or more relevant clinical
endpoints—arm lymphoedema, axillary recurrence, overall survival
at 12 months or longer for each staging strategy, together with
information about SLNB performance (FN and failure rates) to
allow an assessment of applicability to current practice standards
(Mansel et al, 2006; Veronesi et al, 2006; Zavagno et al, 2008;
Canavese et al, 2009; Gill, 2009; Krag et al, 2010). Costs were
estimated from the perspective of the Australian health care
system and included the direct health care costs associated with
the 20-year natural history of breast cancer.
The net effectiveness of each strategy was quantified in terms of
quality-adjusted life years (QALYs; Carr-Hill, 1989). This involves
weighting the time spent in each health state by the health-related
quality-of-life value (utility) associated with that state, where
0¼ death and 1¼ full health. Incremental cost-effectiveness was
measured in terms of the cost per QALY gained. An annual
discount rate of 5% was applied to all future costs and outcomes
(Australian Government, 2011b).
We explored the impact of varying assumptions about both the
costs and effects of each staging strategy within a plausible range
for different clinical settings in a sensitivity analysis.
Model structure
The process defines a set of discrete health states following breast
cancer and a set of probabilities that governs the likelihood of
transitioning from one state to another at the end of each 1-year
cycle (Drummond et al, 2005). The Markov process and health
state transitions used are represented in Figure 1. Each health state
was assigned an estimate of the cost required to provide
appropriate health care over the cycle and a utility weighting that
reflected the QALYs gained per cycle. A half-cycle correction was
used in the Markov process.
Key assumptions about ALND and SLNB outcomes were: ALND
provides only true positive or true negative results to guide
appropriate management. Sentinel lymph node biopsy can also
provide true positive or true negative results, but is also capable of
generating a FN result (defined as a true finding of no metastases
in the sentinel node and any accessory node in a patient who has
occult metastases in other axillary nodes that have not been
sampled), or failing to generate a result at all when the sentinel
node cannot be identified. Patients with a true negative or FN
SLNB finding are classified as having no axillary metastases and do
not receive ALND; both positive SLNB cases and failed SLNB cases
undergo ALND, consistent with current clinical guidelines.
The SLNB performance characteristics, transition
probabilities and health-state utilities used in model
All probabilities and health-state utilities used in the model are
listed in Table 1, together with the ranges applied in the sensitivity
analyses. The hypothetical patient cohort was assigned the average
age (58 years), tumour grade (2) and risk of node-positive disease
(26.9%) of the SNAC population (Gill, 2009). To explore potential
implications of extending SLNB to a higher-risk population, we
repeated our analyses for patients with a risk of lymph node
involvement of 50%, reflecting the probability of lymph node
involvement in patients with large or multifocal primary tumours
(Laura et al, 2006; Behm and Buckingham, 2008; Ozmen et al,
2008).
Data from the SNAC trial was used to estimate rates of SLNB
failure and SLNB FN findings for the base-case analysis. The risk of
axillary recurrence for an FN SLNB was derived from the NSABP-32
trial data (the largest published trial, n¼ 5611, Krag et al, 2010),
by attributing the excess regional node recurrences for patients
with a negative SLNB finding in the SLNB arm, compared with the
ALND arm, entirely to the effect of FNs. This resulted in an
estimated 7.7% of FN SLNB presenting with axillary recurrence
within 5 years. The model was calibrated to reflect evidence that
the risk of recurrence after primary treatment is highest in the first
5 years after diagnosis and diminishes progressively over time
(Saphner et al, 1996).
The utility weights applied to the discrete health states were
obtained from a breast cancer population using the standard
gamble method (Kanis et al, 2003). As we did not find any
published data on the utility of breast cancer patients with
lymphoedema, a ‘disutility’ (quality-of-life decrement) was applied
to patients with moderate-severe lymphoedema. This disutility was
Disease
free
Breast
cancer
surgery
Local
recurrence
Axillary
recurrence
Distant
metastases
Death from
cancer
Death
from other
causes
Figure 1 Health states following primary treatment for early breast
cancer included in the decision model. All patients began the model in the
disease-free state after their primary treatment; the likelihood of moving
from one state to another at the end of a cycle was governed by a series of
transition probabilities. After the first cycle, patients could remain disease
free, or progress to local recurrence, axillary recurrence or distant
metastases. Patients with a local or axillary recurrence could recover and
return to disease free, or progress to a distant metastases. Once diagnosed
with distant metastases, patients could either remain living with the
metastases for the next cycle or else die from cancer. Death from cancer
could only occur following distant metastases, whereas death from non-
breast cancer-related causes could occur at any point in the model. Circular
arrows indicate that patients can remain in this state.
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conservatively assumed to be 0.03 in the base-case analysis, which
has been defined as the smallest clinically important difference in
utility (Nichol and Epstein, 2008). A range of 0.01 to 0.05 was
tested in the sensitivity analysis to reflect the uncertainty
surrounding this estimate. The probability of experiencing
moderate–severe arm lymphoedema following ALND or SLNB
was estimated at 18% and 12%, respectively, based on the propor-
tion of patients in the SNAC trial with an increase in arm volume
of more than 15% after 3 years.
The per-annum risk of non-cancer death was derived from
mortality data for women with a median age of 58 years
(Australian Bureau Of Statistics, 2010).
Resource use and costs used in model
The model took the perspective of the Australian health care
system and included the direct health care costs associated with
the 20-year natural history of breast cancer (Table 2).
The cost of the SLNB and ALND procedures were based on
Australian Revised Diagnosis Related Group (AR-DRG) cost
weights (Australian Government, 2008), adjusted to reflect
length-of-stay data reported by SNAC (Gill, 2009). An additional
cost was added to the inpatient cost of the SLNB procedure to
include lymphoscintigraphy and lymphotropic dye injection costs
(Australian Government, 2011a). The SNAC trial reported higher
rates of postoperative seroma and infection following ALND than
SLNB. It was assumed that the costs associated with these
complications were accounted for in the longer hospital stay for
ALND.
The initial surgery and adjuvant therapy costs were accrued
before the first cycle of the Markov process. A cost was allocated to
each health state on the basis of the resource usage level required
to provide appropriate health care over each (1 year) cycle. A one-
off transition cost was assigned to patients who died, or who
entered the local recurrence or axillary recurrence states.
Resource-use data for the long-term management of breast cancer
were based on Australian clinical guidelines and include inpatient
(AR-DRG), outpatient (medicare benefits schedule) and pharma-
ceutical (pharmaceutical benefits schedule) costs (Australian
Government, 2008; Australian Government, 2011a, b).
RESULTS
Using base-case assumptions, the model estimated that SLNB
results in 1.1 more axillary recurrences per 1000 patients at 5 years,
and 1.9 more axillary recurrences per 1000 patients at 20 years
than ALND (Table 3). The estimated impact of this difference on
the incidence of distant metastases and cancer death at 5 and 20
years are shown in Table 3. On the basis of these results, SLNB is
estimated to be associated with a reduction of 10.4 life years per
1000 patients treated over 20 years. However, when taking into
account the quality-of-life benefit gained by avoiding lymphoede-
ma, SLNB was more effective than ALND, generating an additional
10.2 QALYs per 1000 patients over 20 years (8.2 QALYs after
discounting future gains at 5% per annum; Table 3). Sentinel
lymph node biopsy also saved AU$883 000 per 1000 patients over
20 years compared with ALND after discounting (Table 3).
Sentinel lymph node biopsy remained both more effective and
less costly than ALND when all other parameters in the model were
varied over their plausible range (Table 4).
A multiway sensitivity analysis examined the joint effects of
uncertainty in the parameters for which an efficiency threshold
was identified. Figure 2a shows the results of these parameters
Table 1 SLNB characteristics, transition probabilities and health-state utilities
Range
Variable Base case Low High Source
Proportions
Node positive patientsa 0.269 0.2 0.46 Gill (2009)
SLNB procedures failing 0.06 0.001 0.071 Gill (2009)
FN SLNB result 0.055 0.024 0.166 Gill (2009)
ALND patients experiencing lymphoedema 0.176 0.1312 0.2112 SNAC trial data
SLNB patients experiencing lymphoedema 0.119 0.0416 0.1428 SNAC trial data
Annual probabilities
Local (ipsilateral) recurrence as first eventb 0.0055 0.0044 0.0066 Krag et al (2010)
Axillary recurrence as first eventb 0.0008 0.0006 0.0010 Krag et al (2010)
Given FNb 0.0160 0.0102 0.0689d Krag et al (2010)
Distant metastases
As a first event, node positive 0.0126 0.0109 0.0144 de Bock et al (2009)
As a first event, node negative 0.0063 0.005 0.0075 Veronesi et al (2009)
After local recurrence, node positive 0.1246 0.0997 0.1496 Wapnir et al (2005)
After local recurrence, node negative 0.0772 0.0429 0.0927 Anderson et al (2009)
After axillary recurrence, node positive 0.2063 0.1305 0.2759 Wapnir et al (2005)
After axillary recurrence, node negative 0.2259 0.1674 0.2834 Anderson et al (2009)
Death following distant mets 0.2970 0.2729 0.3313 Gennari et al (2005)
Death from other causes Changes over time — — ABS mortality datac
Utilities
Disease free 0.989 0.79 1 Karnon et al (2008)
Axillary recurrence 0.911 0.73 1 Karnon et al (2008)
Local recurrence 0.911 0.73 1 Karnon et al (2008)
Distant metastases 0.796 0.64 0.96 Karnon et al (2008)
Lymphoedema penalty 0.03 0.05 0.01 Assumption
Abbreviations: ALND¼ axillary lymph node dissection; CI¼ confidence interval; FN¼ false negative; SNAC¼ sentinel node axillary clearance; SNLD¼ sentinel lymph node
biopsy. aSensitivity analysis reflects low 95% CI from SNAC, as well as upper CI from other randomised controlled trials. bProbability halves after the first 5 years, and halves again
after 10 years. cGeneral mortality rate for females aged 55–74, adjusted to exclude breast cancer deaths. dUpper sensitivity estimate is conservatively based on an assumption
that 30% of FNs will present with axillary recurrence after 5 years.
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being simultaneously varied, assuming a population risk of nodal
metastases of 27%. Each panel depicts a threshold plane shaded
according to the preferred strategy (according to the QALYs
generated) for a given combination of parameter estimates. The
upper left-hand panel illustrates that SLNB (dark shading) was
always preferred over ALND (light shading), irrespective of the
estimated probability and disutility of lymphoedema, when the
estimated risk of an FN SLNB and the risk of axillary recurrence,
given an FN SLNB, were set to the lower end of the plausible range.
The lower right-hand panel illustrates that this result was reversed,
with ALND being preferred, when the estimated risk of an FN
SLNB and the risk of axillary recurrence, given an FN SLNB, were
set to the higher end. The panel in the centre illustrates that the
preferred treatment was sensitive to the estimated probability and
disutility of lymphoedema when the risk of an FN SLNB and the
risk of axillary recurrence, given an FN SLNB, were set to the base-
case estimates. When the multiway sensitivity analysis was
repeated for a population with a 50% risk of nodal metastases,
the results were more favourable towards ALND as shown in
Figure 2b.
DISCUSSION
This modelled analysis indicates that SLNB is a more effective and
marginally less costly staging strategy than ALND over a 20-year
follow-up period. The base-case analysis for patients with a low
risk of axillary metastases (e.g., a 60-year-old woman with a 2-cm
tumour, histological grade 2 and non-palpable lymph nodes)
demonstrated that the benefits of avoiding lymphoedema alone
outweighed the potential small long-term risks associated with an
FN SLNB rate of 5.5%, with only a modest cost saving of $883 over
20 years per patient.
Our analysis suggests SLNB remains more effective than ALND,
even in settings where the risk of an FN result is as high as 13%. To
put this threshold value in context, a systematic review of 69 SLNB
Table 2 Resource use and costs
Costsa Source Unit cost ($) Total cost ($)
Treatment
ALND procedure AR-DRG — 5576.45
SLNB-negative procedure AR-DRG, MBS — 4206.38
SLNB positive, ALND following AR-DRG, MBS — 7771.28
SLNB fail, ALND following AR-DRG, MBS — 5576.45
Adjuvant therapyb
Radiotherapy (86% of ALND, 89% of SLNB)c MBS — 5130.40
First-line chemotherapy (30% for ALND, 31% for SLNB)d MBS,PBS — 16 160.43
Endocrine therapy – 5 years (81%) PBS — 10 960.95
Herceptin therapy – 1 year (29%) Cancer Institute, MBS — 64 032.80
Follow-up schedule (annual) — — 254.10
History and examination  2 MBS 82.30 —
Mammography  1 MBS 89.50 —
Lymphoedema (annual) — — 1198.60
Lymphoedema mobility clinic AR-DRG 959.00 —
Outpatient physiotherapy clinic  4 MBS 59.90 —
Local recurrence — — 7658.40
Inpatient major surgical procedure AR-DRG 6393.00 —
Radiotherapy (13%)c MBS 5171.75 —
Specialist visits  4 MBS 82.30 —
GP visits  4 MBS 67.65 —
Axillary recurrence — — 24555.97
Inpatient major surgical procedure AR-DRG 6393.00 —
Radiotherapy (13%)c MBS 5171.75 —
First-line chemotherapy (69%)d MBS, PBS 16 160.43 —
Second-line chemotherapy (31%)d MBS, PBS 18 664.31 —
Specialist visits  4 MBS 82.30 —
GP visits  4 MBS 67.65 —
Distant metastases (annual) — — 24340.11
Inpatient procedure  3 (70%) AR-DRG 5190.33 —
Third-generation chemotherapy (100%)d MBS, PBS 5419.06 —
Fourth-generation chemotherapy (50%)d MBS, PBS 15 172.31 —
Specialist visits  2 MBS 82.30 —
GP visits  4 MBS 67.65 —
End of life costs — — 29615.97
Equivalent to 2 the initial stage of breast cancer Baker et al (1991) — —
Death from other causes Seshamani and Gray (2005) JHE — 8659.10
Abbreviations: ALND¼ axillary lymph node dissection; AR-DRG¼Australian refined diagnostic related groups; MBS¼medicare benefits schedule; PBS¼ pharmaceutical benefits
schedule; SNAC¼ sentinel node axillary clearance; SNLD¼ sentinel lymph node biopsy. aAll costs are varied by 20% in the sensitivity analysis. bThe proportion of patients receiving
each therapy is taken from SNAC. cRadiotherapy costs include an initial and follow-up consultation, computed tomography planning and megavoltage – three fields (breast, boost
and axilla) for 6 weeks. dChemotherapy costs include an initial and follow-up consultation, chemotherapy drug(s), drug administration and ancillary medications.
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accuracy studies conducted between 1970 and 2003 (total 7765
mapped sentinel nodes) found 81% of studies reported an SLNB
FN rate lower than 13% (Kim et al, 2006). Current SLNB surgical
training and quality control procedures aim to achieve FN rates of
5% or lower (Lyman et al, 2005).
We also explored the possible implications of extending SLNB to
patients at higher risk of axillary metastasis where trial evidence is
lacking (e.g., a 35-year-old woman with a 4-cm tumour,
histological grade 3 and nonpalpable lymph nodes). On the basis
of the current practice in which all patients with a positive SLNB
proceed to ALND, our modelled analysis indicates ALND is the
more effective strategy in this patient group (ALND favoured for
patients with risk of axillary metastases 448%, Table 4).
Conclusion in favour of SLNB or ALND also depend on the true
risk of lymphoedema associated with ALND compared with SLNB,
the subjective impact to an individual on the symptoms of
lymphoedema, and the range of uncertainty around the risk of
axillary recurrence due to an FN SLNB. Sentinel lymph node
biopsy became less effective than ALND if the risk of moderate–
severe lymphoedema after ALND was set to 14%, an absolute
risk difference of p2%. Such a small difference is unlikely on
the basis of current trial evidence of differences in lymphoedema
and arm symptoms, including the NSABP-32 (5% difference in
patient-reported moderate–severe arm swelling at 36 months,
Land et al, 2010) and the ALMANAC trial (7% difference in
the proportion of patients reporting substantial arm swelling at
18 months, Fleissig et al, 2005).
Exploring the uncertainty about the longer-term risk of axillary
recurrence after an FN SLNB, we found the 5-year risk of axillary
recurrence after an FN SLNB would need to exceed 19% to
outweigh the benefits of avoiding lymphoedema, that is, at least 1
in 5 patients with an FN SLNB result experienced an axillary
recurrence within 5 years. This probability cannot be directly
measured, but recent clinical trials (Zavagno et al, 2008; Krag et al,
2010; Veronesi et al, 2010) and observational studies (Veronesi
et al, 2009) provide data to estimate that the true risk is lower than
this threshold, including the possibility of no increased risk. The
estimate used for our base-case analysis was derived from 8-year
data reported from NSABP B-32 (Krag et al, 2010). The low risk of
axillary recurrence in this trial may be attributed to the use of
adjuvant therapies; most patients (84%) with a negative SLNB in
this trial received adjuvant endocrine and/or chemotherapy (Krag
et al, 2010), and most receive radiotherapy to the breast and often
the axillary tail of the breast with lower nodes included in those
radiation fields. Recent results from the American College of
Surgeons Oncology Group Z0011 trial provide further evidence
that SLNB is not inferior to ALND in women with one to two
positive sentinel nodes when combined with current adjuvant
radiotherapy and chemotherapy treatments (Giuliano et al, 2011).
For patients with Stage I–IIa disease, representing the average
trial patient, we found that even assuming a modest preference for
avoiding lymphoedema (disutility of 0.03), the avoidance of arm
morbidity through SLNB would outweigh these small potential
risks of FN results. The disutility value of 0.03 has been defined as
the smallest difference in utility that is considered to be clinically
important (Nichol and Epstein, 2008), and in the context of our
model, implies that patients would equate 10 years of life with
moderate–severe lymphoedema to 9.7 years of life in full health. In
contrast, for patients at high risk of axillary metastases, ALND was
more effective than SLNB at a disutility for lymphoedema at 0.03.
However, if patients more strongly preferred avoiding lymphoe-
dema (e.g., disutility 0.04 or more), SLNB would also be more
effective than ALND after taking into account the quality-of-life
benefits of avoiding lymphoedema.
Our results will be helpful in counselling and individualising
surgical treatment decisions for patients with early-stage breast
cancer. Figure 2a and b provide a visual summary of findings from
this study to inform these discussions between surgeons and
Table 3 Modelled estimates of outcomes for SLNB and ALND at 5 and 20 years
After 5 years After 20 years
SLNB ALND Difference SLNB ALND Difference
Cumulative incidences (per 1000)
Axillary recurrence 4.9 3.8 1.1 9.6 7.7 1.9
Distant metastases 44.5 44.2 0.3 174.2 172.8 1.4
Death from cancer 18.9 18.8 0.1 145.5 144.3 1.2
Death from other 18.4 18.4 0.0 159.8 160.1 0.3
Years disease free 4822.50 4823.96 1.5 17 008.65 17 029.40 20.75
Total life years 4926.88 4926.98 0.1 17 571.52 17 581.93 10.41
Cost effectiveness (per 1000)
QALYs discounted 4295.97 4290.92 5.05 11 302.40 11 294.20 8.20
Cost discounted ($AU millions) 46.04 46.66 0.62 57.49 58.38 0.88
Result when discounted Favours SLNBa Favours SLNBa
QALYs undiscounted 4835.7 4830.0 5.7 17 205.2 17 195.0 10.2
Cost undiscounted ($AU millions) 46.63 47.27 0.64 67.01 68.13 1.12
Result when undiscounted Favours SLNBa Favours SLNBa
Abbreviations: ALND¼ axillary lymph node dissection; QALY¼ quality adjusted life year; SLNB¼ sentinel node biopsy. aBase case estimates indicated that SLNB was both
cheaper and more effective than ALND.
Table 4 Results of one-way sensitivity analyses for parameters with cost
or effectiveness thresholds
Parameter description Threshold value
Parameters with effectiveness thresholds
Probability of lymph node positive disease (%) 448
Risk of axillary recurrence given FN SLNB (%) 419
Probability of FN SLNB (%) 413
Probability of lymphoedema in contral arm (i.e., ALND; %) o14
Disutility of lymphoedema o0.0124
Parameters with cost thresholds
Cost SLNB positivea ($) 457 183
Cost SLNB negativea ($) 446 864
Cost ALNDa ($) o46 679
Probability lymph node positive disease (%) 443
Abbreviations: ALND¼ axillary lymph node dissection; FN, false negative;
SLNB¼ sentinel node biopsy. aCost includes both surgery and adjuvant therapy
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patients. Overall, these results highlight the importance of patient
preference in decision-making about SLNB, in particular in women
at high risk of nodal metastases. For patients assessed at low-
average risk of axillary metastases (Figure 2a), the centre box
represents the woman at average risk with an SLNB FN rate fixed at
5.5%, based on the SNAC trial data (middle column) and the axillary
recurrence rate estimated from trial data (middle row). It shows SLNB
(dark shading) is favoured as producing more QALYs than ALND
across a wide range of estimates for the probability of lymphoedema
after ALND and the disutility of lymphoedema. In this scenario, ALND
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Figure 2 Multi-way sensitivity analysis. (A) Individuals with a 27% risk of axillary lymph node metastasis. The blue shading represents the set of
probabilities and disutilities where SLNB leads to more QALYs gained, whereas the green represents the combination of probabilities and disutilities when
ALND produces higher QALYs. *Probability of axillary recurrence over initial 5 years of follow-up. (B) Individuals with a 50% risk of axillary lymph node
metastasis. The blue shading represents the set of probabilities and disutilities where SLNB leads to more QALYs gained, whereas the green represents
the combination of probabilities and disutilities when ALND produces higher QALYs. *Probability of axillary recurrence over initial 5 years of follow-up.
The colour reproduction of this figure is available at the British Journal of Cancer online.
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(light shading) would only be considered more favourable under
extreme assumptions about the low probability of lymphoedema after
ALND, or for patients with a very weak preference for avoiding
lymphoedema. If shifting to a setting where the SLNB FN rate may be
as high as 16.6% (as reported in the GIVOM trial), the middle box in
the right-hand column shows ALND would be more favourable.
However, conclusions would shift to favour SLNB with only moderate
changes in estimates about lymphoedema risk and patient preferences.
Observational studies have indicated patients with tumours over
3 cm, multifocal tumours and tumours with lymphovascular
involvement have a probability of axillary metastases of 50% and
higher (Laura et al, 2006; Behm and Buckingham, 2008; Ozmen et al,
2008). Although awaiting trial direct evidence about the role of SLNB
in these patient groups from ongoing trials, including the SNAC2
trial (Wetzig et al, 2011), Figure 2b illustrates relevant issues when
discussing SLNB and ALND options in these patient groups.
Costs vary between different countries; however, the two major
factors driving differences in costs between SLNB and ALND – the
longer hospital stay and higher risk of lymphoedema associated
with ALND – are likely to be consistent internationally. The SLNB-
based strategy was more expensive than ALND when the cost
difference between the two procedures was less than AU$741 per
patient. We assumed 79% of SLNB-positive procedures incurred a
second operation for ALND at a later date (Gill, 2009). The cost-
effectiveness of SLNB would be even more favourable if it were
possible to identify and manage SLNB-positive cases at the time of
the initial operation, avoiding reoperation and a second hospital
admission. Another driving factor for the size of difference in both
the costs and effects between these strategies is the proportion of
patients offered SLNB, who test positive and proceed to ALND,
incurring the extra costs and associated morbidity for the second
procedure.
This costing does not include the costs borne by the patient and
society. In particular, the modelled costs of lymphoedema are likely to
underestimate the costs to the patient in Australia where access to
publicly funded physiotherapy and occupational therapy services for
lymphoedema are limited. The major strength of this study is to
provide a framework that combines trial evidence of clinical efficacy
and patient preference in individualising surgical treatment decision
for patients with early breast cancer. This modelling approach
provides the unique advantage to assess the relative long-term
morbidities of the two surgical approaches as tradeoffs between
improved quality-of-life and potential small survival reduction for
SLNB compared with ALND. It also provides an evidence-based
estimate of the relative long-term benefits of SLNB over ALND and
the potential impact of extending SLNB to patient groups where
limited evidence is available from clinical trials.
The main limitation is that the model does not capture all
possible consequences of SLNB and ALND. For example, the
benefits of SLNB are limited to an estimation of improved quality-
of-life associated with avoiding arm lymphoedema, and the
potential harms associated with SLNB due to patient anxiety
about the need to proceed to ALND and delay in definitive surgery
are not explored. The model does not attempt to reflect the entire
complexity of practice by mapping out all possible breast cancer
outcomes or treatment strategies. Nevertheless, we believe the
model structure reflects the major sources of differences between
SLNB and ALND that influence long-term cost-effectiveness.
Overall, our finding that a staging strategy using SLNB is both
more effective but marginally less costly than ALND over 20 years
is not unexpected, and is consistent with current clinical guidelines
(Aebi et al, 2010; NCCN, 2011). More intriguing is our finding that
this advantage, 0.0082 QALYs and $883 saved per patient,
appeared to be smaller than the perceived benefits based on
clinical experience and enthusiasm, and consumer demand.
Possible reasons for this discrepancy are: first, that the model
estimate of the patient disutility associated with lymphoedema
does not fully capture the difference in all patient-important
outcomes such as short- and long-term morbidity and the broader
social and financial implications of these outcomes for patients;
second, it is possible that the population benefits of SLNB are more
modest than generally perceived.
Unfortunately, current trials have used different definitions of
lymphoedema, which limits comparisons and pooling of data to
better estimate the benefits of avoiding ALND. There is a need for a
standard clinical definition and criteria for the measurement of
arm lymphoedema for future trial analyses. There is also no
commonly accepted measure of ALND-related quality-of-life.
SLNB trials have each used different validated measurement tools
to report statistically significant health-related quality-of-life
advantages for patients receiving SLNB compared with ALND at
up to 3 years, although the difference in quality-of-life scores
appears to reduce over this time period, with two trials reporting
no significant difference in the overall quality-of-life scores at 2
(Del Bianco et al, 2008) and 3 years (Land et al, 2010). It would be
very valuable if these data were used to derive a more direct
estimate of difference in utility, the measure used to calculate
QALYs, between the two staging strategies for use in decision
models such as ours. Studies to measure the effects of arm
lymphoedema on costs to patient, health system and society are
also needed for more precise estimates of cost-effectiveness.
In conclusion, this model identifies factors that influence SLNB
effectiveness and cost-effectiveness, and hence, are important to
consider when individualising treatment and counselling patients,
as well as identifying areas where more reliable estimates will be of
value. Although the modelled analysis indicates that SLNB is a
cost-effective treatment over 20 years, this does not replace the
need for empirical evidence. Information about the long-term
incidence and disutility of lymphoedema is needed, and will be
particularly helpful to inform decisions for patients at high risk of
axillary metastases. If the quality-of-life benefits of SLNB are found
to be smaller than our modelled estimates, then long-term trial
data will be critical to better estimate or exclude small differences
in cancer outcomes. Well-validated prognostic models will also be
valuable to better select patients for SLNB, who are at low risk of
axillary metastasis or can safely avoid ALND if SLNB is positive.
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